Immune biomarkers in prostate cancer brachytherapy
Part of Cancer, Kidney & urinary clinical trials.
This study looks at immune system markers in men getting brachytherapy (internal radiation) for prostate cancer. It may help us understand how the body responds to this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You are getting brachytherapy (radioactive seeds or temporary implants) for prostate cancer.
- You have not had any previous treatment for prostate cancer (if this is your first treatment).
- You have not had radiation therapy in the last three months before this treatment (if this is a salvage treatment).
- You do not have an autoimmune disease (like lupus or rheumatoid arthritis).
- You are not taking blood-thinning medication (like warfarin or apixaban).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to use a type of internal radiation (high-dose-rate brachytherapy) guided by MRI to treat prostate cancer that has come back in the same area after previous radiation therapy. It is designed to be more precise and hopefully safer while using the latest PSMA PET scans to make sure the cancer hasn't spread.
This trial tests a high-dose radiation treatment (brachytherapy) that places tiny radioactive seeds directly into the area where your prostate was. It is for men whose prostate cancer has returned only in that area after having their prostate removed.
This study tests a focused (“salvage”) brachytherapy—radiation placed directly near the prostate—to treat prostate cancer that has returned after earlier radiation. It may help control the tumor while limiting radiation exposure to surrounding tissues, based on how well people fit the study’s safety and cancer details.
This study looks at a type of radiation therapy called HDR brachytherapy for men with low-risk or slightly higher risk prostate cancer. It aims to understand how your genes affect treatment outcomes.
This trial studies how safe and effective different high-dose radiation levels are for prostate cancer placed directly in the prostate (HDR brachytherapy). It may help by finding a dose that controls the cancer while keeping side effects acceptable.
This trial tests a targeted radiation treatment called HDR brachytherapy for prostate cancer that hasn't spread. It aims to treat only the cancer spots seen on MRI, which may reduce side effects.
Hear when a new Prostate Cancer (Diagnosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.